Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allergies
Researchers from Yamaguchi University report on findings in allergies
May 11th, 2008
"Oligodeoxynucleotides (ODN) with CpG motifs (CpG ODN) induce T helper (Th)1-type reaction. We aimed to evaluate the therapeutic effect of CpG ODN in the development of late allergic rhinitis induced by ovalbumin (OVA), which is one of Th2 diseaes, in BALB/c mice," researchers in Yoshida, Japan report. "Effects of a single dose of synthetic CpG-ODN (50 mu g) intraperitoneally (i.p.) at the priming phase (on day 0) by OVA on the development of late eosinophilic rhinitis at respiratory areas were compared to the control mice treated with its vehicle (ODN without CpG motifs; 50 mu g). Animals were again sensitized by OVA (on day 10) i.p., and 4 days after second...
Source: Pharma Investments, Ventures & Law Weekly (2008-05-11)
|
